Welcome to our dedicated page for Rhythm Pharmaceu SEC filings (Ticker: RYTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
RHYTHM PHARMACEUTICALS director Jean Christophe reported equity awards and an RSU conversion into common stock. He received 2,324 restricted stock units, each representing one share of common stock, which fully vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.
He also received stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, vesting on the same schedule and expiring on June 23, 2036. In addition, 4,712 previously granted restricted stock units were exercised and converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, he holds 11,712 shares of common stock directly.
RHYTHM PHARMACEUTICALS director David W. J. McGirr reported equity compensation and an option-related share issuance. On June 24, 2026, he received 2,324 Restricted Stock Units and a stock option for 3,691 shares of common stock with an exercise price of $107.55 per share, both as grants.
On June 23, 2026, he exercised 4,712 Restricted Stock Units, receiving the same number of common shares, increasing his direct common stock holdings to 11,712 shares. The new option and RSU awards generally vest by June 24, 2027 or immediately before the issuer’s 2027 annual stockholder meeting, subject to his continued service.
RHYTHM PHARMACEUTICALS director Lynn A. Tetreault received new equity awards and exercised existing units. On June 24, 2026, she was granted 2,324 restricted stock units and options for 3,691 shares of common stock at an exercise price of $107.55 per share. The options and these RSUs vest in full on the earlier of June 24, 2027 or the day immediately prior to the company’s 2027 annual stockholder meeting, subject to her continued board service.
On June 23, 2026, 4,712 restricted stock units were converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, she directly holds 11,712 shares of common stock.
RHYTHM PHARMACEUTICALS director Stuart A. Arbuckle reported equity-based compensation and an option exercise. He received 2,324 restricted stock units (RSUs) and stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, expiring on June 23, 2036. He also exercised 4,712 RSUs into 4,712 shares of common stock, bringing his direct common stock holdings to 11,712 shares. The new RSUs and options generally vest in full by June 24, 2027, subject to continued service.
RHYTHM PHARMACEUTICALS director Jennifer L. Good reported equity awards and an option-related share issuance. On June 24, 2026, she received 2,324 restricted stock units and options for 3,691 shares of common stock at an exercise price of $107.55 per share. The new RSUs and options fully vest on the earlier of June 24, 2027 or the day immediately before the company’s 2027 annual stockholder meeting, subject to her continued service. On June 23, 2026, 4,712 previously granted RSUs were converted into 4,712 shares of common stock, increasing her direct common stock holdings to 11,712 shares.
Rhythm Pharmaceuticals reported the results of its Annual Meeting of Stockholders held on June 24, 2026. Shareholders representing 64,146,146 votes, about 92% of the 69,675,938 eligible votes as of the April 27, 2026 record date, participated online or by proxy.
Two Class III directors were elected to terms running until the 2029 annual meeting. David W. J. McGirr received 53,167,971 votes for and 8,704,527 withheld, while David P. Meeker, MD received 59,961,848 votes for and 1,910,650 withheld, with 2,273,648 broker non-votes for each.
Shareholders also ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 63,924,852 votes for and 197,701 against. On an advisory basis, compensation of named executive officers was approved with 50,368,659 votes for, 11,467,157 against and 36,682 abstentions, plus 2,273,648 broker non-votes.
Rhythm Pharmaceuticals director Lynn A. Tetreault reported an exercise-and-sell transaction in company stock. On June 22, 2026, she exercised stock options to acquire 37,000 shares of common stock at $28.27 per share and sold 37,000 shares in open-market transactions at a weighted average price of $100.3215 per share. The sales were executed under a Rule 10b5-1 instruction adopted on December 15, 2025. Following these transactions, she directly holds 7,000 shares of common stock.
Rhythm Pharmaceuticals used this 8-K to highlight new clinical and real‑world data for its MC4R agonist portfolio, led by IMCIVREE (setmelanotide), in Prader‑Willi syndrome (PWS), acquired hypothalamic obesity (HO) and Bardet‑Biedl syndrome (BBS).
Interim six‑month results from an exploratory Phase 2 trial in 18 PWS patients showed a −3.06% mean BMI reduction at Month 6 among 17 treated patients, with adult and pediatric subgroups each around −3% and pediatric patients achieving a −0.35 mean BMI z‑score reduction. DEXA data in 16 patients showed a −4.19% mean fat‑mass loss with a +0.74% lean‑mass gain, while most patients with moderate to severe hyperphagia and elevated anxiety scores achieved clinically meaningful improvements. Safety and tolerability were consistent with the known setmelanotide profile.
Rhythm also updated its PWS epidemiology work, estimating 12,500–16,000 patients in each of the U.S. and Europe and 8,500–12,750 with both hyperphagia and obesity in each region. Additional ENDO 2026 presentations described an −18.9% mean BMI reduction over up to 2.5 years in acquired HO, one‑year oral bivamelagon BMI reductions of −6.7% to −16.6% across dose cohorts, and real‑world BBS data in 286 U.S. patients, where 62% of adults achieved at least 10% body‑weight loss and obesity‑related outpatient visits declined after treatment.
Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith exercised stock options for 3,000 shares of Common Stock at an exercise price of $17.87 per share. This moved 3,000 shares from options into directly held stock, with no shares reported sold in this filing.
Following the transaction, Smith directly owns 119,611 shares of Common Stock and 79,000 stock options that remain outstanding and fully vested. The exercised options were already fully vested, indicating this was a routine conversion of derivative awards into common shares rather than an open-market purchase or sale.